Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
Abstract: Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. In some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly, and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.
Abstract: The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
Type:
Grant
Filed:
July 7, 2021
Date of Patent:
November 26, 2024
Assignee:
Genentech, Inc.
Inventors:
Hui F. Liu, Brian David Kelley, Deanna E. Myers, Beth McCooey, Krista Marie Petty
Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
Type:
Grant
Filed:
March 10, 2021
Date of Patent:
November 26, 2024
Assignee:
Genentech, Inc.
Inventors:
Robert Anthony Blake, Peter Dragovich, Lewis J. Gazzard, Susan Kaufman, Tracy Kleinheinz, Thomas Pillow, Steven T. Staben, Binqing Wei
Abstract: Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
Type:
Application
Filed:
April 6, 2022
Publication date:
November 21, 2024
Applicant:
Genentech, Inc.
Inventors:
Lewis J. GAZZARD, Samantha Alyson GREEN, Elizabeth H. KELLEY, Matthew Leo LANDRY, Sushant MALHOTRA, Benjamin David RAVETZ, Michael SIU, Jack Alexander TERRETT, BinQing WEI, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE, Guosheng WU, Yinlei SUN, Cheng SHAO, Aijun LU, Yulai ZHANG
Abstract: The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
Type:
Application
Filed:
March 13, 2024
Publication date:
November 21, 2024
Applicant:
Genentech, Inc.
Inventors:
Elisia VILLEMURE, Joachim RUDOLPH, Mingshuo ZENG
Abstract: The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated variants, compositions, pharmaceutical compositions, and articles of manufacture comprising the variants, as well as methods of making and characterizing the variants and compositions thereof.
Type:
Grant
Filed:
June 27, 2022
Date of Patent:
November 19, 2024
Assignee:
Genentech, Inc.
Inventors:
Lynn A. Gennaro, Yung-Hsiang Kao, Yonghua Zhang
Abstract: The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
Type:
Grant
Filed:
April 26, 2024
Date of Patent:
November 19, 2024
Assignee:
Genentech, Inc.
Inventors:
Yung-Hsiang Kao, Michael W. Laird, Melody Trexler Schmidt, Rita L. Wong, Daniel P. Hewitt
Abstract: The invention provides novel compounds having the general formula I: wherein R1, X, Z1 to Z5, L, n, the A ring, and the B ring, are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
Type:
Grant
Filed:
January 20, 2021
Date of Patent:
November 12, 2024
Assignee:
Genentech, Inc.
Inventors:
Steven McKerrall, Brian Salvatore Safina, Aleksandr Kolesnikov, Birong Zhang, Wenfeng Liu, Kwong Wah Lai
Abstract: In one embodiment, a method includes, for each of a set of samples, receiving data input that includes dimensions of a sample area, a percentage of the sample area being viable cells, and a percentage of the sample area exhibiting necrosis. The method includes, for each of the set of samples, computing a percentage of the sample area being stroma. The method includes, for each of the set of samples, computing weighting factors. The method includes computing a weighted percentage of the set of samples being viable cells based on the computed weighting factor and percentage of the sample area being viable cells for each of the set of samples. The method includes determining that a specified condition is detected in the set of samples based on the computed weighted percentage of the set of samples being viable cells satisfying a threshold correlating with an indication of the specified condition.
Type:
Grant
Filed:
January 25, 2022
Date of Patent:
November 12, 2024
Assignee:
Genentech, Inc.
Inventors:
Anjali Saqi, Shawn Wen Sun, Kosei Tajima, Barbara Jennifer Gitlitz
Abstract: Multispecific antibodies comprising a first half antibody comprising a first antigen binding site that binds to a polyubiquitin; and a second half antibody comprising a second antigen binding site that binds a pro-inflammatory protein, such as receptor-interacting protein kinase 1 (RIP1) or receptor-interacting protein kinase 2 (RIP2), as well as methods for using the antibodies, are provided.
Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
Type:
Application
Filed:
July 10, 2024
Publication date:
November 7, 2024
Applicant:
Genentech, Inc.
Inventors:
Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.
Abstract: The presently disclosed subject matter relates to targeted integration (TI) host cells suitable for the expression of recombinant proteins, as well as methods of producing and using said TI host cells.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
October 29, 2024
Assignee:
GENENTECH, INC.
Inventors:
Chi Kin Domingos Ng, Yongping Guo Crawford, Amy Shen, Meixia Zhou, Bradley R. Snedecor, Shahram Misaghi, Albert Eric Gao
Abstract: Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
Type:
Grant
Filed:
April 16, 2024
Date of Patent:
October 29, 2024
Assignees:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Mark C. Benyunes, Graham Alexander Ross
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
Abstract: Provided herein are methods for quantifying the concentration of multiple metabolites in a sample. Also provided are methods for relative quantification of multiple metabolites in a sample, methods for monitoring the course of a cell culture, and methods for optimising a cell culture.